The conditional approval for the AstraZeneca therapy was grounded in a detailed scientific review, according to the Emirates Drug Establishment. Dr Ruqaya Al Bastaki, acting executive director of the medical products regulation sector at the EDE, said the establishment’s regulatory framework is grounded in rigorous scientific assessment and balances pharmaceutical advances with the highest standards of safety, quality and efficacy. The decision highlights the UAE’s proactive approach to integrating innovative treatments into its healthcare system while maintaining strict oversight.
Primary immunoglobulin A nephropathy is an immune-mediated kidney disease caused by the deposition of an immune protein in kidney tissue, which can trigger inflammation and a gradual decline in kidney function, the EDE reported. Elevated protein levels in the urine serve as an important indicator of disease progression, the authority noted in its announcement. The new indication for Ultomiris aims to address this by lowering proteinuria and potentially slowing advancement to more severe stages of kidney damage in at-risk adults.
Ultomiris, also known as ravulizumab, has been available in the UAE since 2022 for the management of several rare diseases, according to the drug establishment. This latest approval expands its application to a broader patient population facing chronic kidney challenges. The intravenous infusion is administered as a drip-based treatment under medical supervision for eligible patients.
AstraZeneca welcomed the regulatory milestone, with Gulf Cluster President Sameh El Fangary describing the conditional approval as an important step towards expanding treatment options for patients. In a statement, he said the company looked forward to continuing its collaboration with UAE partners to support access to the treatment for eligible patients, improve treatment outcomes and enhance the quality of care. The pharmaceutical firm has committed to working closely with local health authorities on implementation of the new indication.
This development aligns with the UAE’s We the UAE 2031 vision, which emphasizes innovation and leadership in healthcare and pharmaceuticals, the EDE assessment found. By accelerating access to cutting-edge therapies, the country seeks to improve patient outcomes in specialized fields such as nephrology. The move further cements the UAE’s reputation as a regional pioneer in adopting global medical advancements ahead of other nations.
The EDE continues to evaluate new indications and therapies through its established approval pathways to meet evolving patient needs across the federation, officials indicated. Additional data from ongoing studies may support full approval in the future following the conditional phase. Such regulatory agility has enabled the UAE to lead in several first-in-world approvals for rare and complex conditions in recent years.
ع